| Ytd | 72.57% | |
| 1y | 134.71% |
| Open | 93.29 | Prev Close | 93.29 | Low | 92.24 | High | 94.60 | Mkt Cap | 2.01B |
| Vol | 406.32K | Avg Vol | 346.85K | EPS | 12.84 | P/E | 7.30 | Forward P/E | 6.99 |
| Beta | 1.30 | Short Ratio | 4.52 | Inst. Own | 109.78% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 82.97 | 200-d Avg | 62.53 | 1yr Est | 113.33 |
Citizens analyst David M. Scharf maintains Encore Capital Group (NASDAQ:ECPG) with a Market Outpe
Encore Capital Group, Inc. (NASDAQ:ECPG) (the "Company") today announced its intention to of
Citizens analyst David M. Scharf maintains Encore Capital Group (NASDAQ:ECPG) with a Market Outpe
Truist Securities analyst Mark Hughes maintains Encore Capital Group (NASDAQ:ECPG) with a Buy and
Encore Capital Group (NASDAQ:ECPG) raises FY2026 GAAP EPS guidance from $12.00 to $13.00 vs $11.90 a
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $3.86 per share which beat the analys
Citizens analyst David M. Scharf maintains Encore Capital Gr (NASDAQ:ECPG) with a Market Outperfo
Truist Securities analyst Mark Hughes maintains Encore Capital Gr (NASDAQ:ECPG) with a Buy and ra
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $3.37 per share which beat the analys
Citizens analyst David M. Scharf maintains Encore Capital Gr (NASDAQ:ECPG) with a Market Outperfo
Janney Montgomery Scott analyst John Rowan maintains Encore Capital Gr (NASDAQ:ECPG) with a Buy a
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $3.17 per share which beat the analys
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $1.93 per share which beat the analys
Truist Securities analyst Mark Hughes maintains Encore Capital Gr (NASDAQ:ECPG) with a Buy and lo
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $1.50 per share which missed the anal
Northland Capital Markets analyst Mike Grondahl maintains Encore Capital Gr (NASDAQ:ECPG) with a
JMP Securities analyst David Scharf maintains Encore Capital Gr (NASDAQ:ECPG) with a Market Outpe
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $1.28 per share which missed the anal
JMP Securities analyst David Scharf reiterates Encore Capital Gr (NASDAQ:ECPG) with a Market Outp
Truist Securities analyst Mark Hughes maintains Encore Capital Gr (NASDAQ:ECPG) with a Buy and lo
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $1.34 per share which beat the analys
Encore Capital Group, Inc. (NASDAQ:ECPG), a leading international specialty finance company, today a
Encore Capital priced its offering of $500.0 million aggregate principal amount of 8.500% senior sec
Encore Capital Group, Inc. (NASDAQ:ECPG) (the "Company") today announced its intention to of
Encore Capital Gr (NASDAQ:ECPG) reported quarterly earnings of $0.95 per share which beat the analys
JMP Securities analyst David Scharf reiterates Encore Capital Gr (NASDAQ:ECPG) with a Market Outp
JMP Securities analyst David Scharf reiterates Encore Capital Gr (NASDAQ:ECPG) with a Market Outp
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat
On Thursday, 498 companies reached new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i
On Friday morning, 446 companies hit new 52-week lows.
On Thursday, 930 stocks hit new 52-week lows.
Wednesday's session saw 361 companies set new 52-week lows.
Monday saw 825 companies set new 52-week lows.
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after th
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu